Abstract
Advances in immunosuppressive therapy over the past decade have led to dramatic improvements in graft survival. The immunosuppression that is used is center-dependent and is constantly evolving with the development of new medications. The goal remains to find the best combination that will optimize graft survival, while minimizing the adverse effects.
Copyright 2004 Blackwell Munksgaard
MeSH terms
-
Acute Disease
-
Antibodies, Monoclonal / adverse effects
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Humanized
-
Azathioprine / adverse effects
-
Azathioprine / therapeutic use
-
Child
-
Cyclosporine / adverse effects
-
Cyclosporine / therapeutic use
-
Daclizumab
-
Graft Rejection / prevention & control*
-
Humans
-
Immunoglobulin G / adverse effects
-
Immunoglobulin G / therapeutic use
-
Immunosuppressive Agents / adverse effects
-
Immunosuppressive Agents / therapeutic use*
-
Kidney Transplantation*
-
Muromonab-CD3 / adverse effects
-
Muromonab-CD3 / therapeutic use
-
Mycophenolic Acid / adverse effects
-
Mycophenolic Acid / analogs & derivatives*
-
Mycophenolic Acid / therapeutic use
-
Sirolimus / adverse effects
-
Sirolimus / therapeutic use
-
Tacrolimus / adverse effects
-
Tacrolimus / therapeutic use
-
Treatment Outcome
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Immunoglobulin G
-
Immunosuppressive Agents
-
Muromonab-CD3
-
Cyclosporine
-
Daclizumab
-
Mycophenolic Acid
-
Azathioprine
-
Sirolimus
-
Tacrolimus